EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Monitoring of pulmonary outcomes in paediatric cystic fibrosis patients treated with modulator therapy—a narrative review

José Fontoura-Matias, Natalia S Escobar, Brandon Zanette, Hartmut Grasemann

European Journal of Pediatrics · 16.11.2026 · 185 (12)

DOI: 10.1007/s00431-026-07599-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Pediatrics, online erschienen am 16.11.2026. Verfasst von José Fontoura-Matias und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respiratory Medicine, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, M5G 1X8, Canada. Hauptthemen laut MEDLINE: Cystic Fibrosis. Die Arbeit nennt 122 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recently introduced CFTR modulator drugs have transformed the disease trajectories in people with cystic fibrosis. Children with cystic fibrosis, who would once have experienced progressive lung damage and pulmonary function decline from early life onwards, now, when treated with effective modulators, appear to have preserved lung structure and pulmonary function using conventional monitoring tools. However, since cystic fibrosis lung disease may still progress despite effective therapy, early detection of disease manifestation, disease progression, and the tracking of treatment responses remain crucial. Monitoring of lung disease in the current era of CFTR modulators, therefore, poses a fundamental challenge for cystic fibrosis clinicians and researchers. This narrative review summarises currently available monitoring tools for paediatric cystic fibrosis patients. Conclusion : In children with cystic fibrosis receiving effective CFTR modulator therapy, spirometry remains an important component of pulmonary monitoring but may be insufficient to detect early or residual lung disease. Complementary approaches, including multiple-breath washout, oscillometry, and structural and functional lung imaging, can provide more sensitive assessment of pulmonary abnormalities and treatment responses. Further development of sensitive, non-invasive biomarkers of airway infection and inflammation, alongside evidence to guide the integration of these tools into routine clinical care, remains an important priority. What is Known: • CFTR modulator therapy has transformed clinical outcomes in cystic fibrosis, and children initiating effective modulators early in life frequently maintain normal or near-normal pulmonary function. • Conventional monitoring with spirometry, particularly FEV₁, has limited sensitivity for detecting early or residual cystic fibrosis lung disease. What is New: • Clinical monitoring of cystic fibrosis lung disease in children has shifted towards the use of technologies allowing for detection of subtle, potentially reversible, structural, functional, and inflammatory abnormalities that may persist despite modulator therapy. • Multiple-breath washout, quantitative computed tomography (CT), functional magnetic resonance imaging (MRI) of the chest, as well as emerging biomarkers provide complementary information beyond spirometry and are reshaping contemporary monitoring of CF lung disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisHumansChildRespiratory Function TestsSpirometryCystic Fibrosis Transmembrane Conductance RegulatorAminophenolsLungDisease ProgressionTreatment OutcomeAminopyridinesBenzodioxolesQuinolones

Stichwörter der Autor:innen

CFTR modulator therapyCystic fibrosisLung function monitoringPulmonary imaging

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorAminophenolsAminopyridinesBenzodioxolesQuinolones

Autor:innen und Institutionen

  • Division of Respiratory Medicine, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, M5G 1X8, Canada.
  • Program in Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada.
  • Division of Respiratory Medicine, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, M5G 1X8, Canada. Hartmut.Grasemann@sickkids.ca.
  • Program in Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada. Hartmut.Grasemann@sickkids.ca.

Zitieren

APA

Fontoura-Matias, J., Escobar, N. S., Zanette, B., & Grasemann, H. (2026). Monitoring of pulmonary outcomes in paediatric cystic fibrosis patients treated with modulator therapy—a narrative review. European Journal of Pediatrics, 185(12). https://doi.org/10.1007/s00431-026-07599-7

Vancouver

Fontoura-Matias J, Escobar NS, Zanette B, Grasemann H. Monitoring of pulmonary outcomes in paediatric cystic fibrosis patients treated with modulator therapy—a narrative review. European Journal of Pediatrics. 2026;185(12). doi:10.1007/s00431-026-07599-7

BibTeX
@article{FontouraMatias2026,
  author = {Fontoura-Matias, José and Escobar, Natalia S and Zanette, Brandon and Grasemann, Hartmut},
  title = {Monitoring of pulmonary outcomes in paediatric cystic fibrosis patients treated with modulator therapy—a narrative review},
  journal = {European Journal of Pediatrics},
  year = {2026},
  volume = {185},
  number = {12},
  doi = {10.1007/s00431-026-07599-7}
}
Kostenlos starten →